CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

AdaptHealth posts Q3 loss due to goodwill impairment charge

By Reuters News


Overview

  • US home medical equipment provider's Q3 revenue rose 10.9% yr/yr, slightly missing analyst expectations

  • Company posted a large net loss due to $184.8 mln goodwill impairment

  • Adjusted EBITDA for Q3 fell 2.9% yr/yr


Outlook

  • AdaptHealth raises 2026 net revenue guidance to $2.88 bln-$2.90 bln from $2.85 bln-$2.89 bln

  • Company lifts 2026 adj EBITDA outlook to $510 mln-$525 mln from $490 mln-$520 mln

  • AdaptHealth lowers 2026 free cash flow forecast to $50 mln-$75 mln from $80 mln-$120 mln


Result Drivers

  • CAPITATED AGREEMENT - Co said exclusive capitated agreement with national integrated delivery network improved contract profitability through lower labor costs

  • SEGMENT GROWTH - Co reported organic revenue growth across Sleep Health, Respiratory Health and Wellness at Home segments

  • PORTFOLIO FOCUS - Co said pending sale of Diabetes Health business will allow greater focus on core segments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Miss*

$745.65 mln

$746.45 mln (8 Analysts)

Q3 Loss Per Share

$1.13

Q3 Net Loss

$152.77 mln

Q3 Operating Income

Miss

-$155.92 mln

$38.47 mln (3 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for AdaptHealth Corp. is $9.00, about 52.3% above its November 2 closing price of $5.91

  • The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 10 three months ago


Reuters Recommended Reads

  • Nov 3 - Fresenius Medical cuts 2026 profit outlook as US treatment decline deepens

  • Nov 3 - Henry Schein Q3 sales slightly miss, raises 2026 profit outlook

  • Nov 2 - Hinge Health Q3 revenue jumps 52%, beats estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.